Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Marien O Den Boer"'
Autor:
Paul P Schneider, Xavier G L V Pouwels, Valéria Lima Passos, Bram L T Ramaekers, Sandra M E Geurts, Khava I E Ibragimova, Maaike de Boer, Frans Erdkamp, Birgit E P J Vriens, Agnes J van de Wouw, Marien O den Boer, Manon J Pepels, Vivianne C G Tjan-Heijnen, Manuela A Joore
Publikováno v:
PLoS ONE, Vol 15, Iss 4, p e0230909 (2020)
OBJECTIVE:In breast cancer patients, treatment at the end of life accounts for a major share of medical spending. However, little is known about the variability of cost trajectories between patients. This study aims to identify underlying latent grou
Externí odkaz:
https://doaj.org/article/c542a7f020294eb2862b4ef478cfa91e
Autor:
Sandra M. E. Geurts, Maaike de Boer, M. Wouter Dercksen, Dominique. J. P. Tilli, Vivianne C. G. Tjan-Heijnen, Manon J. Pepels, Khava I.E. Ibragimova, Frans L. G. Erdkamp, Marien O den Boer, Birgit Epj Vriens
Publikováno v:
Cancer Research. 80:P2-08
Background The aim of this study was to determine the subtype conversion rate and the initial systemic treatment choices by subtype for patients diagnosed with advanced breast cancer since 2007 who were included in the SONABRE Registry. Patients and
Autor:
Sandra M. E. Geurts, Marien O den Boer, Khava I.E. Ibragimova, Maaike de Boer, Frans L. G. Erdkamp, Birgit Epj Vriens, Vivianne C. G. Tjan-Heijnen, M. Wouter Dercksen, Manon J. Pepels, Nathalie J. A. Teeuwen
Publikováno v:
Cancer Research. 80:P1-19
Background Previously, we reported that patients with HR+/HER2+ advanced breast cancer diagnosed in 2007-2009 had a better overall survival (OS) than patients with HR-/HER2+ advanced breast cancer (SONABRE Registry, Lobbezoo et al. BCRT 2013). This d
Autor:
Birgit E.P.J. Vriens, Sandra M. E. Geurts, Paul Schneider, Xavier Pouwels, Frans L. G. Erdkamp, Bram Ramaekers, Agnes J. van de Wouw, Marien O den Boer, Khava I. E. Ibragimova, Maaike de Boer, Valéria Lima Passos, Vivianne C. G. Tjan-Heijnen, Manon J. Pepels, Manuela A. Joore
Publikováno v:
PLOS ONE, 15(4):0230909. Public Library of Science
PLoS ONE
PLoS ONE, Vol 15, Iss 4, p e0230909 (2020)
PLoS ONE
PLoS ONE, Vol 15, Iss 4, p e0230909 (2020)
ObjectiveIn breast cancer patients, treatment at the end of life accounts for a major share of medical spending. However, little is known about the variability of cost trajectories between patients. This study aims to identify underlying latent group
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e395e2baaae7f1f7e69c85f2b48aed48
https://cris.maastrichtuniversity.nl/en/publications/237fd765-647b-43ca-9014-fad5794d110b
https://cris.maastrichtuniversity.nl/en/publications/237fd765-647b-43ca-9014-fad5794d110b
Autor:
Andrzej Piwowar, Fransje Aa Valster, Jeffrey P.B.M. Braak, Marije Ie Appels, Frits van Coevorden, Niels H Nielsen, Johanna E.A. Portielje, Jeroen Buijsen, Petra Flygare, Marije Slingerland, Nicole C.T. van Grieken, Jetske M. Meerum Terwogt, Maartje Los, Mattias Elmlund, Henk Boot, Rob L. H. Jansen, Johanna W. van Sandick, A. Haringhuizen, Johannes J. Bonenkamp, Harm van Tinteren, Edwin P.M. Jansen, Henk H. Hartgrink, Jaap De Boer, Anouk K. Trip, Ge Jpm Jonkers, Marie Louise Jespersen, Cecillia Lagerbäck, Per Edlund, Marco B Polée, Mats Perman, J (Hans)-Martin Mb Otten, Marjan A Van Dijk, Danny Houtsma, A (Bert) Jan Ten Tije, Arnold Baars, Olaf Jl Loosveld, Maud M. Geenen, Maarten C.C.M. Hulshof, Gerrit-Jan Veldhuis, Erik W Muller, Geert-Jan Creemers, Annelie Je Vulink, Quirijn A. J. Eijsbouts, Annerie Slot, Diane Grootenboers, Hein Putter, Ellen M Hendriksen, Maurice J.C. van der Sangen, Fabiënne A. R. M. Warmerdam, Tom Rozema, HA A. Maurits Swellengrebel, Henk K Van Halteren, Ate van der Gaast, Marcel Verheij, Richard Van Hilligersberg, Helene Hörberg, Pehr Lind, Annemieke Cats, Cornelis J.H. van de Velde, Jitty M Smit, Alex L. T. Imholz, Donald L. van der Peet, Aart Van Bochove, Henk M.W. Verheul, Adelheid Me Van der Torren-Conze, Frans L. G. Erdkamp, Dick Johan van Spronsen, Mark I. van Berge Henegouwen, Ernst Jan Spillenaar Bilgen, Johanna Mgh Van Riel, Marien O Den Boer, Hanneke W. M. van Laarhoven, Marjolein Em Rentinck, Ron C Rietbroek, Bengt Johansson, David Borg, Anders Johnsson, Aart Beeker, Reinoud J. B. Blaisse, Miriam Koopman, Daan Ten Bokkel Huinink, Karen J. Neelis, Elma Meershoek-Klein Kranenbarg, Djamila Boerma, Heleen M. Ceha, Bea C Tanis, Marie-Cecile Jc Legdeur, O Aart Van Dobbenburgh, Steven Vanhoutvin, Sjoerd Hovenga, Karolina Sikorska, Pètra M Braam, H Pieter van den Berg, Huub van der Mijle, Marianne Nordsmark, Bengt Glimelius
Publikováno v:
lancet oncology, 19(5), 616-628. Lancet Publishing Group
CRITICS investigators 2018, ' Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial ', The Lancet Oncology, vol. 19, no. 5, pp. 616-628 . https://doi.org/10.1016/S1470-2045(18)30132-3
Lancet Oncology, 19, 5, pp. 616-628
CRITICS investigators 2018, ' Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS)-an international, open-label, randomised phase 3 trial ', The Lancet Oncology, vol. 19, no. 5, pp. 616-628 . https://doi.org/10.1016/S1470-2045(18)30132-3
Lancet oncology, 19(5), 616-628. Elsevier Science
Lancet Oncology, 19, 616-628
The Lancet Oncology, 19(5), 616-628
The Lancet Oncology, 19(5), 616-628. Lancet Publishing Group
CRITICS investigators 2018, ' Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial ', The Lancet Oncology, vol. 19, no. 5, pp. 616-628 . https://doi.org/10.1016/S1470-2045(18)30132-3
Lancet Oncology, 19, 5, pp. 616-628
CRITICS investigators 2018, ' Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS)-an international, open-label, randomised phase 3 trial ', The Lancet Oncology, vol. 19, no. 5, pp. 616-628 . https://doi.org/10.1016/S1470-2045(18)30132-3
Lancet oncology, 19(5), 616-628. Elsevier Science
Lancet Oncology, 19, 616-628
The Lancet Oncology, 19(5), 616-628
The Lancet Oncology, 19(5), 616-628. Lancet Publishing Group
Item does not contain fulltext BACKGROUND: Both perioperative chemotherapy and postoperative chemoradiotherapy improve survival in patients with resectable gastric cancer from Europe and North America. To our knowledge, these treatment strategies hav
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b21019f3b155741c37a17771cdb957cb
https://pure.amc.nl/en/publications/chemotherapy-versus-chemoradiotherapy-after-surgery-and-preoperative-chemotherapy-for-resectable-gastric-cancer-critics-an-international-openlabel-randomised-phase-3-trial(8c4f223a-519d-480e-ad66-3d7eaea704e6).html
https://pure.amc.nl/en/publications/chemotherapy-versus-chemoradiotherapy-after-surgery-and-preoperative-chemotherapy-for-resectable-gastric-cancer-critics-an-international-openlabel-randomised-phase-3-trial(8c4f223a-519d-480e-ad66-3d7eaea704e6).html
Autor:
Hans J Braun, Siu W. Lam, Steffen M de Groot, Ankie M.T. van der Velden, Judith R. Kroep, Johanneke E.A. Portielje, Joep Douma, Carolien H. Smorenburg, Aafke H. Honkoop, Monique M.E.M. Bos, Nienke M. Nota, Jetske M. Meerum Terwogt, Joan van den Bosch, Frank Jeurissen, Johanna Mgh van Riel, Bea Tanis, Johan Berends, Epie Boven, Sabine C. Linn, Marien O den Boer, Harm van Tinteren, Maartje Los, Agnes Jager
Publikováno v:
Cancer Research. 75:P3-06
Background The phase II ATX trial aimed at evaluating safety and efficacy of first-line AT or ATX for HER2-negative LR/MBC (NTR1348; BOOG 2006-06). Plasma samples were collected for investigation of circulating proteins involved in angiogenesis and t
Autor:
Jetske M. Meerum Terwogt, Henk-Jan Guchelaar, Judith R. Kroep, Agnes Jager, Jojanneke Ea Portielje, Joep Douma, Johan Berends, Ankie M.T. van der Velden, Steffen M de Groot, Maartje Los, Joan van den Bosch, Frank J.F. Jeurissen, Carolien H. Smorenburg, Aafke H. Honkoop, Hans J Braun, Bea Tanis, Charlotte N Frederiks, Tahar van der Straaten, Sabine C. Linn, Marien O den Boer, Siu W. Lam, Johanna Mgh van Riel, Epie Boven, Monique M.E.M. Bos
Publikováno v:
Cancer Research. 75:P6-08
Background Newly identified SNPs in genes encoding metabolizing enzymes (CYP2C8, CYP3A4) and drug target (TUBB2A) of paclitaxel have been associated with PNP1-3. A recent GWAS has found novel SNPs in EPHA5 and FGD4 possibly predictive for PNP4. Likew
Autor:
Jaap Wals, Geerard L. Beets, Philippe Lambin, Marien O Den Boer, Guido Lammering, Jeroen W. A. Leijtens, Jeroen Buijsen, Meindert N. Sosef, Rob L. H. Jansen, Robert G. Riedl, Jan Theys
Publikováno v:
Radiotherapy and Oncology
Radiotherapy and Oncology; Vol 107
Radiotherapy and Oncology, 107(2), 184-188. Elsevier Ireland Ltd
Radiotherapy and Oncology; Vol 107
Radiotherapy and Oncology, 107(2), 184-188. Elsevier Ireland Ltd
Purpose To investigate the toxicity of nelfinavir, administered during preoperative chemoradiotherapy (CRT) in patients with locally advanced rectal cancer. Material and methods Twelve patients were treated with chemoradiotherapy to 50.4 Gy combined
Publikováno v:
European journal of pharmacology. 190(1-2)
The study concerns the effects of indorenate, a tryptamine derivative with antihypertensive properties as well as high affinity for the 5-HT1A binding site, on carotid haemodynamics in anaesthetized pigs. Intracarotid infusions of indorenate (0.3, 1.